AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18394495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Power Laser (LPL)
Number of subjects: 60
Study 16945048 — intervention group
Group type: COMPARATOR
Intervention: Heparin flushes (3 ml of porcine heparin 100 U/ml, 300 U per catheter lumen at least once/day)
Number of subjects: 49
Study 16945048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin flushes (3 ml of lepirudin 100 microg/ml, 300 microg per catheter lumen at least once/day)
Number of subjects: 49
Study 15292740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU x d(‐1) alpha‐tocopherol)
Number of subjects: 38
Study 15292740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 38
Study 11315234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 50 mg/day
Number of subjects: 2293
Study 11315234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 200 mg/day
Number of subjects: 2293
Study 11315234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2293
Study 9415907 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction, nonreinfusable wound drains
Number of subjects: 136
Study 8216439 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray preparation (Isoket Spray) 2.5 mg per valve release
Number of subjects: 18
Study 8216439 — intervention group
Group type: COMPARATOR
Intervention: Reference spray preparation
Number of subjects: 18
Study 8216439 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-2-mononitrate (IS-2-MN) from test spray
Number of subjects: 18
Study 8216439 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide-2-mononitrate (IS-2-MN) from reference spray
Number of subjects: 18
Study 8216439 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) from test spray
Number of subjects: 18
Study 8216439 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide-5-mononitrate (IS-5-MN) from reference spray
Number of subjects: 18
Study 2890019 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment Campylobacter pylori status
Number of subjects: 39
Study 2890019 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture positive for Campylobacter pylori
Number of subjects: 39
Study 2890019 — intervention group
Group type: COMPARATOR
Intervention: Culture negative for Campylobacter pylori
Number of subjects: 39
Study 2890019 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of Campylobacter pylori after apparent eradication
Number of subjects: 39
Study 2890019 — intervention group
Group type: COMPARATOR
Intervention: No recurrence of Campylobacter pylori
Number of subjects: 39
Study 2890019 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of Campylobacter pylori
Number of subjects: 39
Study 31331265 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote electrical neuromodulation (REN)
Number of subjects: 99
Study 31331265 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study 28380313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medication (CLM) during endocrine therapy
Number of subjects: 8010
Study 25723719 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) with either 50% or 65% carbohydrate (CHO)
Number of subjects: 32
Study 25723719 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding (RF) with low or high glycaemic index CHO
Number of subjects: 32
Study 25723719 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 32
Study 25723719 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight re-gain
Number of subjects: 32
Study 23349298 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CM)
Number of subjects: 18
Study 23349298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 21209140 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist service (medication reviews, feedback to physicians, drug treatment discussions, medication reports)
Number of subjects: 345
Study 21209140 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 345
Study 21209140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients who received the intervention
Number of subjects: 345
Study 19128534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-tasking training program (5 weeks, twice-daily practice)
Number of subjects: 19
Study 19128534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19
Study 19128534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-tasking training program
Number of subjects: 19
Study 17134890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant/ondansetron/dexamethasone
Number of subjects: 1032
Study 17134890 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron/dexamethasone
Number of subjects: 1032
Study 17134890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant-based regimen
Number of subjects: 1032
Study 17134890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 1032
Study 15607090 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced 3D MR voiding urethrography (CE 3D MRVU)
Number of subjects: 23
Study 11276541 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention delivered by nurse facilitators over 18 months (July 1997 to December 1998)
Number of subjects: 46
Study 11276541 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention delivered by nurse facilitators
Number of subjects: 46
Study 11276541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 9505772 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 85
Study 9505772 — intervention group
Group type: COMPARATOR
Intervention: Late extubation
Number of subjects: 85
Study 7839480 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment
Number of subjects: 89
Study 7839480 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 89
Study 2905808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.02 mg/kg) followed by Ro 15‐1788 (0.03 mg/kg)
Number of subjects: 10
Study 2905808 — intervention group
Group type: COMPARATOR
Intervention: Ro 15‐1788 (0.03 mg/kg) alone
Number of subjects: 10
Study 2905808 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Ro 15‐1788
Number of subjects: 10
Study 2905808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.02 mg/kg)
Number of subjects: 10
Study 2905808 — intervention group
Group type: COMPARATOR
Intervention: Ro 15‐1788 (0.03 mg/kg)
Number of subjects: 10
Study 2905808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam group prior to administration
Number of subjects: 10
Study 30193927 — intervention group
Group type: EXPERIMENTAL
Intervention: LE gel 2 times a day
Number of subjects: 514
Study 30193927 — intervention group
Group type: EXPERIMENTAL
Intervention: LE gel 3 times a day
Number of subjects: 514
Study 30193927 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 514
Study 27349272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal dexmedetomidine (5 µg)
Number of subjects: 120
Study 27349272 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (100 µg)
Number of subjects: 120
Study 24141709 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Risers conduct problems prevention program
Number of subjects: 223
Study 22537244 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of chocolate (70% cocoa) daily (Group A)
Number of subjects: 90
Study 22537244 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 90
Study 19915454 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 50 mg every 12 hrs, increased as needed up to 200 mg every 12 hrs
Number of subjects: 36
Study 19915454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18279409 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (100,000 IU)
Number of subjects: 34
Study 18279409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15751775 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/didanosine/efavirenz (arm A)
Number of subjects: 36
Study 15751775 — intervention group
Group type: COMPARATOR
Intervention: tenofovir/didanosine/efavirenz without lopinavir/r (arm B)
Number of subjects: 36
Study 15751775 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics of VF patients
Number of subjects: 36
Study 15751775 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance mutations detected
Number of subjects: 36
Study 12913375 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical environment (bedside) for learning and recall
Number of subjects: 63
Study 12913375 — intervention group
Group type: COMPARATOR
Intervention: Educational environment (classroom) for learning and recall
Number of subjects: 63
Study 10947303 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (1.5 mg/kg/day for an average of 10 days)
Number of subjects: 163
Study 10947303 — intervention group
Group type: COMPARATOR
Intervention: Atgam (15 mg/kg/day for an average of 9.7 days)
Number of subjects: 163
Study 8707759 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0
Study 8707759 — intervention group
Group type: COMPARATOR
Intervention: Transfusion therapy
Number of subjects: 0
Study 2004962 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated with oral contrast
Number of subjects: 115
Study 2004962 — intervention group
Group type: COMPARATOR
Intervention: Simulated without oral contrast
Number of subjects: 115
Study 6364442 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ioniser
Number of subjects: 20
Study 6364442 — intervention group
Group type: COMPARATOR
Intervention: Placebo ioniser
Number of subjects: 20
Study 6364442 — intervention group
Group type: COMPARATOR
Intervention: No ioniser
Number of subjects: 20
Study 30935524 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (high dose [24 mg], sustained-release formulation)
Number of subjects: 40
Study 30935524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29454227 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Carnitine 2g/day for one week
Number of subjects: 40
Study 29454227 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with placebo
Number of subjects: 40
Study 27543374 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography (STE) based RV global longitudinal strain (GLS)
Number of subjects: 57
Study 27543374 — intervention group
Group type: EXPERIMENTAL
Intervention: RV GLS cutoff value of ‐18%
Number of subjects: 57
Study 27543374 — intervention group
Group type: COMPARATOR
Intervention: Traditional echocardiographic function parameters
Number of subjects: 57
Study 25070319 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.06 to 0.24 mg/kg/d) for 6 months to 11 years
Number of subjects: 31
Study 23278572 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg EN101
Number of subjects: 0
Study 23278572 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg EN101
Number of subjects: 0
Study 23278572 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg EN101
Number of subjects: 0
Study 20399588 — intervention group
Group type: EXPERIMENTAL
Intervention: sarpogrelate
Number of subjects: 22
Study 19060999 — intervention group
Group type: EXPERIMENTAL
Intervention: T3-T4 sympathectomy
Number of subjects: 64
Study 19060999 — intervention group
Group type: COMPARATOR
Intervention: T4 sympathectomy
Number of subjects: 64
Study 15716161 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative joke subtest
Number of subjects: 16
Study 15716161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon subtest
Number of subjects: 16
Study 15716161 — intervention group
Group type: EXPERIMENTAL
Intervention: Covarying comprehension of nonliteral language and proverbs
Number of subjects: 16
Study 14504455 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with melancholic depression (N1 scale)
Number of subjects: 930
Study 14504455 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with melancholic depression (N1 scale)
Number of subjects: 930
Study 14504455 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall severity and symptomatology of depression
Number of subjects: 930
Study 10564628 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and skills-training program emphasizing double gloving
Number of subjects: 149
Study 10564628 — intervention group
Group type: COMPARATOR
Intervention: Control group (third-year students)
Number of subjects: 149
Study 8732611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiopentone (group I)
Number of subjects: 92
Study 8732611 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane inhalation (group II)
Number of subjects: 92
Study 8732611 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal methohexitone (group III)
Number of subjects: 92
Study 2057023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 2231
Study 2057023 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 2231
Study 2057023 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive cardiac procedures
Number of subjects: 2231
Study 2057023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery among those who underwent catheterization
Number of subjects: 2231
Study 6214438 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg desogestrel + 0.050 mg ethinylestradiol
Number of subjects: 16
Study 6214438 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol
Number of subjects: 16
Study 6214438 — intervention group
Group type: COMPARATOR
Intervention: Both contraceptive combinations
Number of subjects: 16
Study 31357887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination
Number of subjects: 301
Study 31357887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 31357887 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe alone
Number of subjects: 301
Study 31357887 — intervention group
Group type: COMPARATOR
Intervention: Bempedoic acid alone
Number of subjects: 301
Study 31357887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination
Number of subjects: 301
Study 31298268 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling video intervention (n = 54)
Number of subjects: 104
Study 31298268 — intervention group
Group type: COMPARATOR
Intervention: Written information (comparison group, n = 50)
Number of subjects: 104
Study 28618568 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-law distribution
Number of subjects: 0
Study 28618568 — intervention group
Group type: EXPERIMENTAL
Intervention: Γ distribution
Number of subjects: 0
Study 28618568 — intervention group
Group type: EXPERIMENTAL
Intervention: δ-function distribution
Number of subjects: 0
Study 26816332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 16
Study 26816332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24692082 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant letrozole (LET) administered for 24-28 weeks before surgery
Number of subjects: 503
Study 22207299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerecyte coils
Number of subjects: 500
Study 22207299 — intervention group
Group type: COMPARATOR
Intervention: bare platinum coils
Number of subjects: 500
Study 20175427 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulating short bouts of running at 70% of maximum oxygen uptake in six 5‐min bouts with 85 min rest between runs
Number of subjects: 10
Study 20175427 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting throughout the day)
Number of subjects: 10
Study 20175427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise and control trials
Number of subjects: 10
Study 17471547 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplements (20 gm/day for 8 days, then 3 gm/day)
Number of subjects: 37
Study 17471547 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplements
Number of subjects: 37
Study 17471547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 15239231 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar scissors
Number of subjects: 30
Study 15239231 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 30
Study 17661604 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion for 6 months
Number of subjects: 89
Study 10822073 — intervention group
Group type: COMPARATOR
Intervention: Heparin and aspirin (group 1)
Number of subjects: 27
Study 10822073 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban and aspirin (group 2)
Number of subjects: 27
Study 8867254 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain stimulation
Number of subjects: 0
Study 8867254 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine administration
Number of subjects: 0
Study 8867254 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 0
Study 1639946 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous melatonin (2.5 mg, orally) during the daytime (n = 6)
Number of subjects: 12
Study 1639946 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of endogenous nocturnal melatonin secretion by atenolol (100 mg; n = 6)
Number of subjects: 12
Study 1639946 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime melatonin administration
Number of subjects: 12
Study 1639946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal melatonin suppression
Number of subjects: 12
Study 6712031 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose recombinant alpha-2 interferon (50 X 10(6) U/m2 body surface area, intravenously)
Number of subjects: 20
Study 6712031 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose recombinant alpha-2 interferon (1 X 10(6) U/m2, subcutaneously)
Number of subjects: 20
Study 6712031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high and low doses of recombinant alpha-2 interferon
Number of subjects: 20
Study 30226424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas syringae pv. actinidiae strains from China
Number of subjects: 269
Study 30226424 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese strains of Pseudomonas syringae pv. actinidiae
Number of subjects: 269
Study 30226424 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain Jzhy2 from China
Number of subjects: 269
Study 30226424 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains from China
Number of subjects: 269
Study 30226424 — intervention group
Group type: EXPERIMENTAL
Intervention: All strains including K3 isolated in 1997 from Jeju, Korea
Number of subjects: 269
Study 30226424 — intervention group
Group type: EXPERIMENTAL
Intervention: K3 and biovar 1 strains (K3, Kw30, and Psa92)
Number of subjects: 269
Study 29059451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administration
Number of subjects: 11
Study 29059451 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 11
Study 27173976 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-on (contact force data available)
Number of subjects: 117
Study 27173976 — intervention group
Group type: COMPARATOR
Intervention: CF-off (contact force data not available)
Number of subjects: 117
Study 27173976 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-on
Number of subjects: 117
Study 27173976 — intervention group
Group type: COMPARATOR
Intervention: CF-off
Number of subjects: 117
Study 24476536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine injection of 500 IU of human chorionic gonadotropin (hCG) before embryo transfer
Number of subjects: 210
Study 24476536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hCG injection)
Number of subjects: 210
Study 23176133 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice usual care supplemented with an individualised exercise programme of strengthening and stretching exercises
Number of subjects: 480
Study 23176133 — intervention group
Group type: COMPARATOR
Intervention: Best practice usual care (joint protection advice, general exercise advice, functional splinting and assistive devices)
Number of subjects: 480
Study 20665209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (5, 10, and 20 mg/10 ml)
Number of subjects: 9
Study 20665209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone (5, 10, and 20 mg/10 ml)
Number of subjects: 9
Study 20665209 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5, 10, and 20 mg/10 ml)
Number of subjects: 9
Study 20665209 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 9
Study 17968156 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative short-term radiotherapy (5 x 5 Gy)
Number of subjects: 1861
Study 17968156 — intervention group
Group type: COMPARATOR
Intervention: TME alone (no radiotherapy)
Number of subjects: 1861
Study 15610250 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1860
Study 15610250 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1860
Study 11939936 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg)
Number of subjects: 301
Study 11939936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 9704792 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus (SLE)
Number of subjects: 33
Study 9704792 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibody
Number of subjects: 33
Study 9704792 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic villitis
Number of subjects: 33
Study 8580691 — intervention group
Group type: EXPERIMENTAL
Intervention: More concentrated PAP (10 ml = 15 grams of Astragalus)
Number of subjects: 115
Study 8580691 — intervention group
Group type: COMPARATOR
Intervention: Less concentrated PAP (10 ml = 5 grams of Astragalus)
Number of subjects: 115